Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.22.4
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Statement Of Income And Comprehensive Income [Abstract]    
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,903,813) $ (12,074,119)
Foreign currency translation adjustment (47,501) (51,646)
Comprehensive loss to MAIA Biotechnology, Inc. shareholders $ (4,951,314) $ (12,125,765)